The phase 2 AZALEA-TIMI 71 trial in AF shows "an overwhelming reduction" in major and clinically relevant nonmajor bleeding with investigational Factor XI inhibitor abelacimab vs rivaroxaban.
After evidence of “overwhelming reduction” in bleeding compared to Bayer and J&J’s Xarelto, Anthos Therapeutics has ended its Phase II atrial fibrillation study for abelacimab ahead of schedule.